Spasticity is considered an important neural contributor to muscle hypertonia in children
with cerebral palsy (CP). It is most often treated with antispasticity medication, such as …

Background and purpose To support clinical decision‐making in central neurological disorders,
a physical examination is used to assess responses to passive muscle stretch. However, …

Aim Botulinum toxin gives a local tone reduction by blocking neurotransmission at the motor
endplate (MEP). The importance of using MEP‐targeted injections is demonstrated in …

Background Gait classification systems (GCSs) aim to aid clinicians and researchers in
categorizing the gait of pathological populations, with the intent to improve the communication …

Several studies indicated that walking with an ankle foot orthosis (AFO) impaired third rocker.
The purpose of this study was to evaluate the effects of two types of orthoses, with similar …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range of …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A)
in the treatment of children with cerebral palsy (CP), with a special focus on the lower limb. …

Advanced biomechanical analysis of muscle function during gait relies on the use of a
musculoskeletal model. In clinical practice, personalization of the model is usually limited to …

Cerebral palsy (CP) is a heterogeneous group of motor disorders attributed to a non-progressive
lesion in the developing brain. Knowledge on skeletal muscle properties is important to …

Botulinum neurotoxin type-A (BoNT) injections are commonly used as spasticity treatment in
cerebral palsy (CP). Despite improved clinical outcomes, concerns regarding harmful …